Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Composition for prophylaxis or treatment of il-8 related diseases
US2021301011A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2021301011-A1 |
| Application number | US-202117333256-A |
| Country | US |
| Kind code | A1 |
| Filing date | May 28, 2021 |
| Priority date | Aug 5, 2016 |
| Publication date | Sep 30, 2021 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.
First claim
Opening claim text (preview).
1 - 15 . (canceled) 16 . A method for treating an IL-8-related disease, which comprises administering an anti-IL-8 antibody that binds to human IL-8 to a subject in need thereof, wherein the IL-8-related disease is selected from adenomyosis and post-surgical adhesion; and wherein the anti-IL-8 antibody comprises: (a) the amino acid sequence of SEQ ID NO: 23 as HVR-H1, (b) the amino acid sequence of SEQ ID NO: 29 as HVR-H2, (c) the amino acid sequence of SEQ ID NO: 30 as HVR-H3, (d) the amino acid sequence of SEQ ID NO: 26 as HVR-L1, (e) the amino acid sequence of SEQ ID NO: 31 as HVR-L2, and (f) the amino acid sequence of SEQ ID NO: 32 as HVR-L3. 17 . The method of claim 16 , wherein the anti-IL-8 antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 34 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 35. 18 . The method of claim 17 , wherein the anti-IL-8 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 36 and a light chain comprising the amino acid sequence of SEQ ID NO: 38. 19 . The method of claim 17 , wherein the anti-IL-8 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 37 and a light chain comprising the amino acid sequence of SEQ ID NO: 38. 20 . The method of claim 16 , wherein the disease is adenomyosis. 21 . The method of claim 17 , wherein the disease is adenomyosis. 22 . The method of claim 18 , wherein the disease is adenomyosis. 23 . The method of claim 19 , wherein the disease is adenomyosis. 24 . The method of claim 16 , wherein the disease is post-surgical adhesion. 25 . The method of claim 17 , wherein the disease is post-surgical adhesion. 26 . The method of claim 18 , wherein the disease is post-surgical adhesion. 27 . The method of claim 19 , wherein the disease is post-surgical adhesion.
Assignees
Inventors
Classifications
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title
characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin · CPC title
Framework region [FR] · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2021301011A1 cover?
- For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.
- Who is the assignee on this patent?
- Chugai Pharmaceutical Co Ltd, Univ Jichi Medical, Nat Inst Biomedical Innovation Health & Nutrition
- What technology area does this patent fall under?
- Primary CPC classification C07K16/244. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Sep 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).